Myasthenia Gravis Clinical Trial
Official title:
A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis
Verified date | April 2022 |
Source | DAS-MG, Inc |
Contact | Martine Francis, BA |
Phone | 301-343-8894 |
martine[@]mafinc.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | April 30, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. diagnosed with myasthenia gravis and who are currently taking pyridostigmine and experienced pyridostigmine-related GI side effects within the past 7 days. 2. GSRS rating of at least Moderate discomfort on questions 5, 11, and 12. 3. Subjects must be willing and able to complete a GI symptom diary within a consistent timeframe on a daily basis. 4. Subjects must be able to tolerate a pyridostigmine dose of 30mg TID. 5. Must be clinically stable in judgement of treating neurologists for past 3 months. 6. Must have AchR antibody positive MG. 7. Subjects must be able to swallow liquids. 8. Subjects must be in good health as determined by their medical history, physical examination, vital signs, and laboratory tests. A subject with a medical abnormality may be included only if the investigator or designee considers that the abnormality will not introduce significant additional risk to the subject's health or interfere with study objectives. 9. Subjects must have signed an informed consent form indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions. Exclusion Criteria: Key exclusion criteria: The criteria for exclusion of a subject from enrollment in the study are as follows: 1. Any acute or chronic diseases which are associated with GI distress (such as nausea, vomiting, or diarrhea), which could interfere with the subjects' safety during the trial, expose them to undue risk, or interfere with the study objectives. 2. History or presence of hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs. 3. History of substance abuse, known drug addiction, or positive test for drugs of abuse or alcohol. 4. Patients currently using marijuana for any reason (medical or recreational). 5. Known hypersensitivity to pyridostigmine, or to ondansetron or similar 5-HT3 serotonin receptor antagonists. 6. ECG changes including QT interval prolongation and congenital long QT syndrome. Electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmia's or other medicinal products that lead to QT prolongation. 7. Treatment with drugs affecting peripheral cholinergic transmission within 1 month of study entry (with the exception of pyridostigmine). 8. Subjects unlikely to co-operate during the study, and/or be questionably compliant in the opinion of the investigator. 9. Patients currently being treated with narcotics. 10. Patients being treated with aminoglycoside antibiotics, which are contraindicated in myasthenia gravis. 11. Patients unable to be contacted in case of an emergency. 12. Intake of an investigational drug within 30 days of study entry. 13. Pregnancy and women of childbearing potential not willing to follow the birth control requirements as described in the informed consent or breastfeeding. 14. History or presence of obstructive pulmonary disease or urinary obstruction (contraindication for pyridostigmine). 15. This use of selective serotonin reuptake inhibitors (SSRI's). |
Country | Name | City | State |
---|---|---|---|
United States | George Washinton University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
DAS-MG, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with change in the gastrointestinal (GI) side effects | difference in GI side effects as measured by the GSRS-self (Gastrointestinal System Rating Scale - self-administered) | 6 weeks | |
Secondary | Number of participants with change in the side effects | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0" . Incidence and nature of adverse events | 6 weeks | |
Secondary | Number of participants with change in in physical examine | physical examination changes General appearance,Head, eyes, ears, nose, and throat, Respiratory, Cardiovascular, Musculoskeletal, Abdomen, Neurologic, Extremities, Dermatologic, Lymphatic) | 6 weeks | |
Secondary | Number of participants with change in in clinical laboratory evaluations | changes in clinical laboratory evaluations (Creatinine, Potassium(K+),Sodium (Na+) , Chloride (Cl-), Magnesium (Mg++), Calcium, Inorganic phosphate, Glucose, Urea,Bilirubin (Total) ,Bilirubin (direct), AST, ALT, GGT, Alkaline phosphatase, Total Protein, Albumin,Hematocrit Hemoglobin Platelet count Red blood cell (RBC) count WBC count WBC differential Mean cell volume (MCV) Mean cell hemoglobin (MCH) MCH concentration (MCHC) | 6 weeks | |
Secondary | Number of participants with change in Electrocardiography (ECG) | ECG (standard digital 12-lead in singlicate) | 6 weeks | |
Secondary | Plasma concentrations of pyridostigmine | Cmax | 6 weeks | |
Secondary | Plasma concentrations of ondansetron | Cmax | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05039190 -
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
|
Phase 3 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT01727193 -
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
|
Phase 3 | |
Completed |
NCT00285350 -
Mycophenolate Mofetil in Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
Completed |
NCT05694234 -
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
|
||
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Not yet recruiting |
NCT05095103 -
Immune Profiles in Myasthenia Gravis
|
||
Not yet recruiting |
NCT04965987 -
Oxaloacetate in Myasthenia Gravis
|
Phase 1 | |
Terminated |
NCT02102594 -
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
|
Phase 2 | |
Completed |
NCT02066519 -
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
|
N/A | |
Completed |
NCT02774239 -
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
|
Phase 3 | |
Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
Terminated |
NCT01828294 -
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
|
Phase 1 | |
Terminated |
NCT00727194 -
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
Completed |
NCT04590716 -
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
|
||
Recruiting |
NCT04837625 -
Study of Myasthenic Crisis in China
|
||
Not yet recruiting |
NCT01469858 -
Perception and Multisensory Integration in Neurological Patients Using fMRI
|
N/A | |
Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
Completed |
NCT03205306 -
Myasthenia Gravis and Psyche
|